Drug Profile

Mopidamol

Alternative Names: OLX 102; RA 233; Rapenton

Latest Information Update: 27 Mar 2002

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Boehringer Ingelheim Pharma KG
Developer Antigenics; Boehringer Ingelheim Pharma KG
Class Pyrimidines; Small molecules
Mechanism of Action Immunostimulants; Phosphoric diester hydrolase inhibitors; Thromboxane receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Marketed Cancer metastases
Discontinued Non-small cell lung cancer; Ovarian cancer; Thrombosis

Most Recent Events

27 Mar 2002 Launched for Cancer metastases in Germany (IV)
07 Feb 2001 No-Development-Reported for Cancer metastases in Germany (IV)
12 Jan 2000 Discontinued-Clinical for Ovarian cancer in Finland (IV)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com